Buoyed by increasing life spans & lifestyle diseases, the global pharma sector posted a robust YOY growth of 7% for 2006 to register turnovers 
of $643 billion, and there’s no doubting the sustainability of this growth story. But the same can’t be said for individual players, big or small, who are looking up every strategy in the book to churn out those magical numbers.
They came, they saw, they conquered, they bloated and then they fell like a pack of cards. The R&D giants of the pharma industry have faint memories of the heady days in the 1990s, when the blockbuster drugs were making a killing in the market and making headlines. Today, these companies are still making headlines… but not for blockbuster drugs, but blockbuster restructuring plans! The story is the same, be it Pfizer, Merck or GlaxoSmithKline. Furthermore, they are facing an unprecedented scourge from developing economies, keen on invoking the compulsory licensing clause of the TRIPs agreement, a further blow to their efforts towards discovering new drugs. As pharmaceutical giants continue to grope in the dark on their way towards revival, there are quite a few ominous indications that the entire landscape of the global pharmaceutical industry is undergoing massive transformation.
of $643 billion, and there’s no doubting the sustainability of this growth story. But the same can’t be said for individual players, big or small, who are looking up every strategy in the book to churn out those magical numbers.They came, they saw, they conquered, they bloated and then they fell like a pack of cards. The R&D giants of the pharma industry have faint memories of the heady days in the 1990s, when the blockbuster drugs were making a killing in the market and making headlines. Today, these companies are still making headlines… but not for blockbuster drugs, but blockbuster restructuring plans! The story is the same, be it Pfizer, Merck or GlaxoSmithKline. Furthermore, they are facing an unprecedented scourge from developing economies, keen on invoking the compulsory licensing clause of the TRIPs agreement, a further blow to their efforts towards discovering new drugs. As pharmaceutical giants continue to grope in the dark on their way towards revival, there are quite a few ominous indications that the entire landscape of the global pharmaceutical industry is undergoing massive transformation.
For Complete IIPM Article, Click here
Source: IIPM Editorial, 2006
An IIPM and Management Guru Prof. Arindam Chaudhuri's Initiative
Source: IIPM Editorial, 2006
An IIPM and Management Guru Prof. Arindam Chaudhuri's Initiative
IIPM, Business College Ranking India BBA Institute India, IIPM IIPM - Nikhil Khade Online Welcome to 4Ps Business and Marketing The IIPM Think Tank IIPM New Delhi India Professor Arindam Chaudhuri, Renowned Management Guru & Economist IIPM Info Planning and Entrepreneurship Programme, IIPM New Delhi, India Business And Economy IIPM Placements New Delhi, India IIPM Business Management Institute India
